Regulatory bodies play a crucial role in providing guidelines for off-label use. They also encourage pharmaceutical companies to conduct post-market surveillance and additional studies to gather more data on the safety and efficacy of drugs used off-label in neonates. This ongoing research can eventually lead to official approval for these indications.
